Helix Investment Research
Long only, special situations, contrarian, growth

Illumina: Thermo Fisher-Life Deal Unlikely To Threaten Its Market-Leading Position

On April 15, Life Technologies (NASDAQ:LIFE) ended its strategic review, which culminated in a sale of the company to Thermo Fisher Scientific (NYSE:TMO). At $76 per share (in cash), the takeover represents a 12% premium to Life's close on April 12, and a premium of over 30% relative to where the company was trading prior to confirming that it was in the process of conducting a strategic review. From the perspective of Life Technologies, the price seems fair; the $76 offer represents an all-time high for Life, and at the company's current trading price of just over $73, shares have returned nearly 50% so far in 2013. Few analysts or existing Life investors have expressed opposition...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details